Early insulin release effectively improves glucose tolerance: Studies in two rodent models of type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 3, Issue 2, 2001, Pages 85-95

  Gagen, K ^a   Chen, W ^a   Dragonas, N ^a   De Souza, Christopher J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

A 4166; Glipizide; High fat fed; Insulin resistance; Nateglinide; OGTT; Oral glucose load; Zucker

Indexed keywords

GLIPIZIDE; GLUCOSE; INSULIN; NATEGLINIDE; PARACETAMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HYPOGLYCEMIA; HYPOTHESIS; INDWELLING CATHETER; INSULIN RELEASE; INSULIN RESISTANCE; JUGULAR VEIN; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET DISEASE; PATHOLOGY; RAT; RAT STRAIN; RODENT; STOMACH EMPTYING; TIME;

EID: 0034861583     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00115.x     Document Type: Article

References (43)

1. Pathogenesis of NIDDM: A balanced overview
2. Insulin secretion in diabetes mellitus
3. Diminished B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus
4. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes
5. Pathogenesis and treatment of type 2 (non-insulin-dependent) diabetes mellitus (NIDDM)
6. Beta-cell dysfunction, rather than insulin sensitivity, is the primary defect in familial type 2 diabetes
7. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM
8. Insulin resistance and beta cell function in the development of non-insulin-dependent diabetes mellitus: Prospective studies of Pima Indians
9. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
10. Effects of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans
11. Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in noninsulin-dependent diabetes mellitus
12. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
13. Loss of early phase insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose
14. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type-2 diabetic patients
15. Different effects of glyburide and Glip on insulin secretion and hepatic glucose production in normal and NIDDM subjects
16. The relationship between early release and glucose tolerance in healthy subjects
17. The acute effects of preprandial exogenous and endogenous sulfonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes
18. New non-sulfonlyurea insulin secretagogues
19. The metabolic advantages of rapid onset/short duration insulinotropic agents on prandial glucose excursions
20. N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds: A new class of hypoglycemic agents
21. Influence of food intake on the absorption and effects of Glip in diabetic and in healthy subjects
22. Fat feeding causes widespread in vivo insulin resistance, decreases energy expenditure, and obesity in rats
23. The Zucker-fatty rat: A review
24. The measurement of gastric emptying in conscious rats by monitoring serial changes in serum acetaminophen level
25. LiCl and CCK inhibit gastric emptying and feeding and stimulate OT secretion in rats
26. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM
27. Banting Lecture, 1988: Role of insulin resistance in human disease
28. Natural history of β-cell dysfunction in NIDDM
29. β-cells in type II diabetes mellitus
30. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: Role of hepatic and extrahepatic tissues
31. The direct and indirect effects of insulin on hepatic glucose production in vivo
32. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance
33. Inhibition of dipeptidyl peptidase IV with NVP-DPP. 728 increases plasma GLP-1 (7-36 amide) concentration and improves oral glucose tolerance in obese Zucker rats
34. Effects of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl-cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursions: Comparison with voral glucose loadiobse and glibenclamide
35. Mechanism of abnormal oral glucose tolerance of genetically obese fa/fa rats
36. Glucose clamp technique: A method for quantifying insulin secretion and resistance
37. Hormonal regulation of mammalian glucose transport
38. Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile
39. Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166)
40. Hypoglycemic action of phenylalanine derivatives
41. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study